KRYS — Krystal Biotech Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousLarge CapHigh Flyer

Annual income statement for Krystal Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	0	0	0	50.7	291
Cost of Revenue
Gross Profit	—	—	—	47.6	270
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses	33	68.3	145	60.4	225
Operating Profit	-33	-68.3	-145	-9.73	65.7
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	-32.2	-69.6	-140	12.9	95.4
Provision for Income Taxes
Net Income After Taxes	-32.2	-69.6	-140	10.9	89.2
Net Income Before Extraordinary Items
Net Income	-32.2	-69.6	-140	10.9	89.2
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-32.2	-69.6	-140	10.9	89.2
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-1.71	-3.13	-4.51	-1.66	4.18